RESUMO
In the United States, of the 1.1 million persons infected with human immunodeficiency virus (HIV) and the 2.7 million infected with hepatitis C virus (HCV), approximately 16% and 50%, respectively, are unaware of their infection. Highly effective treatments have turned both diseases into manageable conditions, and in the case of hepatitis C, a disease that can be cured. Early diagnosis is imperative so that infected persons can take measures to stay healthy, get into care, benefit from therapy, and reduce the risk of transmission. In this report, we review current recommendations provided by the Centers for Disease Control and Prevention (CDC) and the United States Preventive Services Task Force on whom to screen for HIV and HCV infections, and recommendations from the CDC, the Association of Public Health Laboratories, and the Clinical and Laboratory Standards Institute on how to test for these infections.
Assuntos
Infecções por HIV/epidemiologia , HIV , Hepacivirus , Hepatite C/epidemiologia , Centers for Disease Control and Prevention, U.S. , Feminino , HIV/fisiologia , Infecções por HIV/diagnóstico , Hepacivirus/fisiologia , Hepatite C/diagnóstico , Humanos , Masculino , Programas de Rastreamento/legislação & jurisprudência , Programas de Rastreamento/métodos , Programas de Rastreamento/normas , Estados Unidos/epidemiologia , United States Food and Drug AdministrationRESUMO
Hepatitis C virus infection is a significant public health problem in the United States and an important cause of morbidity and mortality. Recent reports document HCV infection increases among young injection drug users in several US regions, associated with America's prescription opioid abuse epidemic. Incident HCV infection increases among young injectors who have recently transitioned from oral opioid abuse present an important public health challenge requiring a comprehensive, community-based response. We summarize recommendations from a 2013 Office of HIV/AIDS and Infectious Disease Policy convening of experts in epidemiology, behavioral science, drug prevention and treatment, and other research; community service providers; and federal, state, and local government representatives. Their observations highlight gaps in our surveillance, program, and research portfolios and advocate a syndemic approach to this emerging public health problem.
Assuntos
Hepatite C/epidemiologia , Abuso de Substâncias por Via Intravenosa/epidemiologia , Adolescente , Distribuição por Idade , Epidemias , Feminino , Hepatite C/prevenção & controle , Humanos , Incidência , Masculino , Programas de Rastreamento , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Prevenção Primária , Saúde Pública , Pesquisa , Vigilância de Evento Sentinela , Distribuição por Sexo , Abuso de Substâncias por Via Intravenosa/terapia , Estados Unidos/epidemiologiaRESUMO
OVERVIEW: Over the past 15 years, the incidences of hepatitis A and B virus infection in the United States have declined significantly. By contrast, the incidence of hepatitis C virus infection, formerly stable or in decline, has increased by 75% since 2010. Suboptimal therapies of the past, insufficient provider awareness, and low screening rates have hampered efforts to improve diagnosis, management, and treatment of viral hepatitis. New screening recommendations, innovations in assessment and treatment, and an updated action plan from the U.S. Department of Health and Human Services (HHS) seem likely to lead to significant progress in the coming years. This article reviews the epidemiology, natural history, and diagnosis of viral hepatitis; discusses new screening recommendations, assessment tools, and treatments; and outlines the HHS action plan, focusing on the role of nurses in prevention and treatment.